Author:
Guaraldi F.,La Selva R.,Samà M. T.,D’Angelo V.,Gori D.,Fava P.,Fierro M. T.,Savoia P.,Arvat E.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference22 articles.
1. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982. doi:
10.1200/JCO.2014.59.4358
2. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. doi:
10.1038/nrc3239
3. Rossi E, Sgambato A, De Chiara G, Ciardiello F, Gridelli C (2016) Thyroid-induced toxicity of check-point inhibitors immunotherapy in the treatment of advanced non-small cell lung cancer. J Endocrinol Diabetes 3:1–10
4. Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11:e0160221. doi:
10.1371/journal.pone.0160221
5. Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R (2017) US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. doi:
10.1158/1078-0432.CCR-16-0712
(epub ahead of print)
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献